NASDAQ:ARWR
$36.74
(
-0.730%
)
Friday, 3rd Feb 2023
Arrowhead Research Corporation Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $28.52 | $38.96 | Friday, 3rd Feb 2023 ARWR stock ended at $36.74. This is 0.73% less than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 4.09% from a day low at $36.23 to a day high of $37.71. |
| 90 days | $27.75 | $41.03 | |
| 52 weeks | $26.81 | $56.25 |
Historical Arrowhead Research Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $36.36 | $37.71 | $36.23 | $36.74 | 611 328 |
| 2023-02-02 | $35.75 | $37.01 | $35.47 | $37.01 | 726 080 |
| 2023-02-01 | $34.85 | $35.88 | $34.27 | $35.29 | 767 956 |
| 2023-01-31 | $33.51 | $35.03 | $33.51 | $34.99 | 854 449 |
| 2023-01-30 | $33.20 | $33.80 | $32.89 | $33.28 | 807 921 |
| 2023-01-27 | $33.29 | $34.08 | $33.21 | $33.61 | 427 156 |
| 2023-01-26 | $33.24 | $33.76 | $32.60 | $33.28 | 591 938 |
| 2023-01-25 | $33.44 | $33.82 | $32.22 | $32.97 | 756 175 |
| 2023-01-24 | $32.53 | $34.15 | $32.23 | $33.92 | 799 619 |
| 2023-01-23 | $33.66 | $33.69 | $32.28 | $32.70 | 1 232 614 |
| 2023-01-20 | $34.48 | $34.50 | $33.14 | $33.76 | 843 790 |
| 2023-01-19 | $35.84 | $36.13 | $33.90 | $33.93 | 907 829 |
| 2023-01-18 | $37.11 | $37.66 | $35.64 | $35.99 | 828 000 |
| 2023-01-17 | $36.81 | $37.67 | $36.17 | $36.91 | 937 663 |
| 2023-01-13 | $35.99 | $37.95 | $35.62 | $36.82 | 1 037 600 |
| 2023-01-12 | $34.36 | $36.17 | $33.75 | $36.15 | 938 300 |
| 2023-01-11 | $33.07 | $35.42 | $32.47 | $34.42 | 1 657 748 |
| 2023-01-10 | $30.27 | $33.05 | $29.84 | $33.03 | 1 850 057 |
| 2023-01-09 | $30.05 | $31.00 | $28.52 | $30.28 | 3 497 428 |
| 2023-01-06 | $37.47 | $38.32 | $35.58 | $37.38 | 946 000 |
| 2023-01-05 | $37.50 | $38.05 | $36.77 | $37.09 | 873 728 |
| 2023-01-04 | $38.80 | $38.96 | $37.84 | $38.08 | 1 074 366 |
| 2023-01-03 | $40.80 | $41.03 | $36.96 | $38.51 | 1 402 762 |
| 2022-12-30 | $39.77 | $40.62 | $39.61 | $40.56 | 787 669 |
| 2022-12-29 | $38.08 | $40.41 | $37.59 | $40.12 | 1 047 881 |
| 2022-12-28 | $38.31 | $38.98 | $37.18 | $37.56 | 563 198 |
| 2022-12-27 | $38.51 | $39.00 | $37.90 | $38.12 | 706 070 |
| 2022-12-23 | $38.24 | $38.78 | $37.17 | $38.30 | 776 668 |
| 2022-12-22 | $36.64 | $38.25 | $36.34 | $38.21 | 1 239 780 |
| 2022-12-21 | $33.29 | $37.24 | $33.05 | $37.10 | 1 719 784 |
| 2022-12-20 | $31.00 | $33.36 | $30.98 | $32.94 | 848 655 |
| 2022-12-19 | $31.79 | $31.99 | $30.01 | $31.07 | 815 726 |
| 2022-12-16 | $31.00 | $32.10 | $30.86 | $31.77 | 2 446 416 |
| 2022-12-15 | $32.34 | $32.58 | $31.22 | $31.44 | 665 006 |
| 2022-12-14 | $32.79 | $33.44 | $32.35 | $32.85 | 606 725 |
| 2022-12-13 | $32.88 | $33.52 | $31.81 | $32.85 | 782 258 |
| 2022-12-12 | $30.39 | $31.94 | $30.12 | $31.85 | 759 846 |
| 2022-12-09 | $31.34 | $31.35 | $30.18 | $30.24 | 771 350 |
| 2022-12-08 | $33.14 | $33.34 | $31.38 | $31.56 | 618 433 |
| 2022-12-07 | $32.15 | $33.06 | $31.86 | $32.86 | 647 765 |
| 2022-12-06 | $31.74 | $32.11 | $31.32 | $32.01 | 777 111 |
| 2022-12-05 | $33.71 | $33.71 | $31.19 | $31.82 | 888 081 |
| 2022-12-02 | $31.97 | $34.18 | $31.37 | $33.93 | 878 802 |
| 2022-12-01 | $32.31 | $33.29 | $31.80 | $32.02 | 772 669 |
| 2022-11-30 | $30.62 | $32.24 | $30.03 | $32.20 | 1 568 241 |
| 2022-11-29 | $28.00 | $31.70 | $27.75 | $29.99 | 1 775 843 |
| 2022-11-28 | $29.30 | $29.69 | $28.00 | $28.00 | 997 567 |
| 2022-11-25 | $29.29 | $29.81 | $29.12 | $29.50 | 507 121 |
| 2022-11-23 | $29.55 | $29.95 | $29.07 | $29.40 | 605 083 |
| 2022-11-22 | $30.10 | $30.10 | $28.81 | $29.55 | 1 091 342 |
About Arrowhead Research Corporation
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
